We study the phase structure of the random-plaquette Z 2 lattice gauge model in three dimensions. In this model, the"gauge coupling" for each plaquette is a quenched random variable that takes the value β with the probability 1 − p and −β with the probability p. This model is relevant for the recently proposed quantum memory of toric code. The parameter p is the concentration of the plaquettes with "wrong-sign" couplings −β, and interpreted as the error probability per qubit in quantum code.In the gauge system with p = 0, i.e., with the uniform gauge couplings β, it is known that there exists a second-order phase transition at a certain critical "temperature", T (≡ β −1 ) = T c = 1.31, which separates an ordered(Higgs) phase at T < T c and a disordered(confinement)
Room temperature (RT) bistable switching materials continue to fascinate the scientists since they can be utilized for a new class of molecular-based switches or memories. While the spin crossover (SCO) compound is categorized into these attractive materials, designing of a SCO system showing desirable bistability (i.e., wide hysteresis loop spanning RT) in a rational way is still a very challenging issue. We report herein a new family of neutral molecular iron(II) complexes showing hysteretic SCO in a wide range of switching temperatures (239–409 K) and hysteresis widths (1–31 K) spanning RT. These materials were obtained as single crystals of two solvent-free compounds [FeII(ptm2-dmpn)(NCS)2] (1; ptm2-dmpn = N,N′-bis[(1-phenyl-1H-1,2,3-triazol-4-yl)methylene]-2,2-dimethylpropane-1,3-diamine) and [FeII(p-ttm2-dmpn)(NCS)2] (2; p-ttm2-dmpn = N,N′-bis[(1-p-tolyl-1H-1,2,3-triazol-4-yl)methylene]-2,2-dimethylpropane-1,3-diamine), and two solvatomorphs [FeII(p-ttm2-etpn)(NCS)2]·solvent (p-ttm2-etpn = N,N′-bis[(1-p-tolyl-1H-1,2,3-triazol-4-yl)methylene]-1-ethylpropane-1,3-diamine, and solvent = 0.5H2O and 0.5MeCN·0.5MeOH·H2O for 3a and 3b, respectively). All compounds are constructed of a three-dimensional (3D) flexible supramolecular network by multiple weak CH···S hydrogen bonds incorporating an additional orderly dimensional structure by aromatic interactions (i.e., π–π and CH···π interactions) between adjacent aromatic rings of tetradentate ligands. These 3D networks can accommodate a number of molecular motions such as (1) NCS bending, (2) tetradentate ligand biting, (3) aromatic ring rotation, and (4) propylene fragment oscillation to various degrees depending on a slight modification of small alkyl substituents and lattice solvents. The present crystal engineering approach of introducing concerted multimolecular motions into a 3D flexible network can be a new designing concept for controlling switching temperature and cooperativity in a systematic way toward the discovery of unprecedented RT bistable SCO materials.
A novel palladium(IV) complex consisting of a C 2-symmetrical palladaspirocycle framework and an ether ligand was assembled only in a single step from commercially available Pd2(dba)3, tetrachloro-1,2-benzoquinone (o-chloranil), and norbornene. The solid-state structure was confirmed by X-ray analysis of a THF complex. The ligand exchange from diethyl ether to pyridine converted the trigonal-bipyramidal complex to a distorted-octahedral bis(pyridine) complex. Similar palladium(IV) spirocyclic complexes were also formed from the reaction of Pd2(dba)3 with o-chloranil and benzonorbornadiene. The benzonorbornadiene-derived complexes exhibited pronounced stability in both the solid state and solution. The complete decomposition of the mono(pyridine) complex required several hours in C6D6 at 70 °C, and the addition of extra pyridine retarded the decomposition rate. Benzonorbornadiene was obtained as the main organic product, together with two isomeric adducts between o-chloranil and benzonorbornadiene. On the other hand, the decomposition of the pyridine complex took place within 15 min even at −40 to −50 °C, upon exposure to HCl in a CDCl3 solution.
Palladium(0) and platinum(0) precursor complexes, Pd2(dba)3 and Pt(dba)2, reacted with p-benzoquinone (bq) and norbornene (nbe) to afford new dinuclear complexes possessing p-benzoquinone as a bridging ligand and norbornene as a monodentate ligand, Pd2(bq)2(nbe)2 and Pt2(bq)2(nbe)2, respectively. The solid-state structure of the obtained complexes presented the short metal−metal distances similar to predecessors possessing the significant d10−d10 bonding interaction. The formations of the previously reported mononuclear p-benzoquinone and p-naphthoquinone complexes using 1,5-cyclooctadiene in place of norbornene were also unambiguously confirmed by the single-crystal X-ray diffraction studies. The present dinuclear palladium complex proved to be an efficient catalyst precursor for the linear cotrimerization of 1-octene and dimethyl acetylenedicarboxylate. On the other hand, the platinum analogue catalyzed the hydrosilylation of styrene under mild reaction conditions.
Summary:Case reportA 12-year-old girl was referred to our hospital in May Donor leukocyte infusion (DLI) was carried out on a 12-year-old girl with Philadelphia chromosome-positive 1995. Laboratory data revealed that leukocytes were 67 000/l, RBC was 429 × 10 4 /l, platelets were acute lymphoblastic leukemia (Ph ؉ ALL) who received allogeneic bone marrow transplantation from an HLA-4. brother. She developed acute pancreatitis due to l-asparaginase, delaying the BMT schedule by 14 days. BM aspirfollowing BMT. Keywords: acute lymphoblastic leukemia; bone marrow ation just before conditioning contained 5% leukemic cells and fluorescence in situ hybridization (FISH) analysis using transplantation; donor leukocyte infusion; Philadelphia chromosome; reverse transcriptase-polymerase chain reaca BCR-ABL-specific probe was positive. Conditioning was with busulfan 4 mg/kg/day on days −7 and −6; melphalan tion 70 mg/m 2 /day on days −5, −4 and −3; TBI 3 Gy × 2 on days −2 and −1. The total number of nucleated cells harvested from the donor was 3.4 × 10 8 /kg of recipient body The prognosis of Philadelphia chromosome-positive acute weight. GVHD prophylaxis consisted of MTX 15 mg/m 2 lymphoblastic leukemia (Ph + ALL) is very poor. 1 Bone on day +1, 10 mg/m 2 on days +3, +6, +11, and once a week marrow transplantation (BMT) is the most effective thereafter. The patient engrafted normally (neutrophils modality of treatment for Ph + ALL. Nevertheless, recur-Ͼ0.5 × 10 9 /l on day +16, platelets Ͼ20 × 10 9 /l on day +21). rence of original disease remains one of the major obstacles No GVHD developed until day +32. RT-PCR was perforin the treatment of Ph + ALL. 2-5 Donor leukocyte infusion med using primers to detect BCR-ABL chimeric mRNA. (DLI) is a promising modality for patients relapsing after Briefly, total cellular RNA was isolated according to the BMT.6-11 The efficacy of DLI for ALL patients relapsing guanidine isothiocyanate phenol/chloroform method. PCR after BMT has been less effective, 9,10 although there have was performed by the nested PCR using two oligonucleobeen several reports that DLI was effective for relapsing tide primers, 5′-CGCTCTCCCTCGCAGAACTC-3′ and 5′-CML patients after BMT. [6][7][8] GGCCCATGGTACCAGGAGTG-3′ for the first step and Reverse transcriptase-polymerase chain reaction (RT-5′-CGCATGTTCCGGGACAAAAGC-3′ and 5′-GTTTCT-PCR) is a very sensitive method for detecting minimal CCAGACTGTTGACTG-3′ for the second step. PCR conresidual disease (MRD) in Ph + ALL. Miyamura et al 12 ditions consisted of 60 s at 94°C, 60 s at 65°C and 90 s at reported that patients with Ph + ALL who received BMT 72°C for 35 cycles at each step. Amplified PCR products would relapse within 3-9 weeks if the RT-PCR became were separated by electrophoresis on 2% Nu Sieve GTG positive after BMT.agarose and 1% agarose gels. If two independent We report a case of Ph + ALL, where the RT-PCR researchers got different results, an additional four tests remained positive after BMT, who successfully received were performed. RT-PCR were checked ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.